Leerink Swann assumed coverage on shares of Inflarx (NASDAQ:IFRX) in a research note issued to investors on Monday morning, Marketbeat reports. The brokerage issued an outperform rating and a $31.00 price objective on the stock.
Separately, J P Morgan Chase & Co began coverage on Inflarx in a report on Monday. They issued an overweight rating and a $30.00 target price for the company.
Inflarx (NASDAQ:IFRX) traded down $1.08 during trading on Monday, hitting $17.58. The company’s stock had a trading volume of 92,900 shares, compared to its average volume of 57,095. Inflarx has a twelve month low of $14.47 and a twelve month high of $22.48.
Inflarx Company Profile
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company’s primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases.
What are top analysts saying about Inflarx NV? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Inflarx NV and related companies.